Tomas Kiselak
CIK 1830177 · last filed 2026-07-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$312.62M
Companies
9
Total Filings
20
Lifetime Open-Market Net
-$463.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 3,601,316 | $15.70 | $56.54M | $49.50M | 1 | 2026-07-20 |
| VRDN | Director | — | $19.51 | — | $0 | 7 | 2026-07-02 |
| APGE | Director | 51,166 | $134.17 | $6.86M | -$534.10M | 3 | 2026-06-11 |
| SYRE | Director | 406,038 | $99.96 | $40.59M | $0 | 2 | 2026-05-29 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 2,904,000 | $28.69 | $83.32M | $0 | 1 | 2026-02-12 |
| ORKA | Director | 2,573,308 | $90.45 | $232.76M | $0 | 1 | 2025-09-19 |
| DNTH | Director | 0 | $101.61 | $0 | $815.0K | 3 | 2024-10-01 |
| ZBIO | Director | 1,003,814 | $32.29 | $32.41M | $20.40M | 1 | 2024-09-16 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 1 | 2020-10-29 |
Recent Filings · Page 2 of 2
20 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-28 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2024-05-28 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2024-04-01 | APGE | Other (J) | — | $0 | EDGAR |
| 2023-12-29 | SYRE | Other (J) | −15,740,424 | $0 | EDGAR |
| 2023-09-13 | DNTH | Mixed | +72,762 | $815.0K | EDGAR |
| 2023-06-16 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2021-06-16 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2021-02-08 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2020-10-29 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–20 of 20
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.